Bloss J D, Liao S Y, Buller R E, Manetta A, Berman M L, McMeekin S, Bloss L P, DiSaia P J
Department of Obstetrics & Gynecology, University of California, Irvine Medical Center, Orange 92668.
Gynecol Oncol. 1993 Sep;50(3):347-51. doi: 10.1006/gyno.1993.1223.
Since the establishment of extraovarian peritoneal serous papillary carcinoma (EPSPC) as a clinical entity in 1959, less than 250 cases have been described and its clinicopathologic features remain obscure. The present series is a retrospective, case-controlled study comparing the response and survival to cytoreductive surgery followed by cisplatin-based multiagent chemotherapy of 33 women with confirmed EPSPC versus 33 cases with papillary serous ovarian cancer (PSOC). Each EPSPC case was matched to a PSOC control for extent and distribution of disease prior to and following cytoreductive surgery, tumor grade, patient age, and treatment. Additionally, the new Gynecologic Oncology Group criteria for the diagnosis for EPSPC are discussed. There were no significant differences in tumor response to therapy, disease-free interval, and actuarial survival between cases and controls. These data suggest that EPSPC is clinically similar to PSOC and support the need for a prospective clinical trial to compare these two entities further.
自1959年将卵巢外腹膜浆液性乳头状癌（EPSPC）确立为一种临床实体以来，所报道的病例不到250例，其临床病理特征仍不明确。本系列研究是一项回顾性病例对照研究，比较了33例确诊为EPSPC的女性与33例乳头状浆液性卵巢癌（PSOC）患者在接受细胞减灭术和顺铂为主的多药化疗后的反应和生存率。每例EPSPC病例均与1例PSOC对照在细胞减灭术前和术后的疾病范围和分布、肿瘤分级、患者年龄及治疗情况方面进行匹配。此外，还讨论了妇科肿瘤学组关于EPSPC诊断的新标准。病例组和对照组在肿瘤对治疗的反应、无病间期和精算生存率方面均无显著差异。这些数据表明，EPSPC在临床上与PSOC相似，并支持开展一项前瞻性临床试验以进一步比较这两种实体的必要性。
